Asahi Kasei’s Hovilpri wins FDA approval after PRIOH-1 trial demonstrates superior lesion healing
FDA approves Hovilpri for refractory HSV after 63% lesion healing in Phase 3. See how pritelivir changes treatment and Asahi Kasei's outlook.
Medical Devices & Diagnostics
Pharma & Biotech
What the $46m Veloxis Pharmaceuticals settlement means for Envarsus XR
Veloxis Pharmaceuticals will pay over $46 million over Envarsus XR conduct. See why five years of compliance oversight could matter even more.